Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1094038 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.12Day +0.90%Mkt cap $19M1Y −18.8%Off 52W high −54.5%Vol (1Y) 83.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,101 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.0% of sh out |
| Days to cover2.0d |
| 13F net flow (QoQ)−0.53% |
| Top-10 13F concentration91.2% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.9M |
| Earnings (TTM)-$10.9M |
| ROE−68.8% |
| Net margin−343.0% |
| ROIC−21499.5% |
| Sales growth 3Y0.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−24.8% |
| 1Y−18.8% |
| 3Y−77.8% |
| 5Y−94.6% |
| 10Y−97.9% |
| Since incept. (ann.)−39.8% |
Total return through 2026-07-30 · series begins 2014-03-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)83.8% |
| Ann. volatility (3Y)101.2% |
| Sharpe (1Y)0.13 |
| Sharpe (3Y)−0.02 |
| Max drawdown (1Y)−49.3% |
| Max drawdown (3Y)−87.1% |
| Beta (3Y vs SPY)2.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| NEA Management Company, LLC | 1.6M | $2M | 9.75% | +0.0% |
| Blue Owl Capital Holdings LP | 554,250 | $720,525 | 3.32% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 389,319 | $506,115 | 2.34% | new |
| Aisling Capital Management LP | 325,370 | $422,981 | 1.95% | +0.0% |
| RENAISSANCE TECHNOLOGIES LLC | 175,294 | $227,882 | 1.05% | +41.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 160,910 | $209,206 | 0.97% | +23.5% |
| OSAIC HOLDINGS, INC. | 93,121 | $121,057 | 0.56% | −1.4% |
| VANGUARD FIDUCIARY TRUST CO | 87,269 | $113,450 | 0.52% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.16 | — | $751,691 | +115.3% |
| 2025-12-31 | 2026-03-18 | — | — | $1.1M | −51.0% |
| 2025-09-30 | 2025-11-13 | −$0.12 | — | $1.2M | −36.0% |
| 2025-06-30 | 2025-08-14 | −$0.29 | — | $861,184 | −26.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Grant 50% · Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia 13% · National Institutes Of Health Small Business Innovation Research For Lymphoma Grant 9% · Cprit Pancreatic Grant 8% · National Institutes Of Health Small Business Innovation Research 7%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
